Pretransplant mogamulizumab against ATLL might increase the risk of acute GVHD and non-relapse mortality.
about
Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphomaPreclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?Successful treatment with mogamulizumab followed by allogeneic hematopoietic stem-cell transplantation in adult T-cell leukemia/lymphoma: a report of two cases.Striving to cure adult T-cell leukaemia/lymphoma: a role for allogeneic stem cell transplant?Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance.HLA-haploidentical hematopoietic stem cell transplantation with low-dose thymoglobulin GVHD prophylaxis for an adult T cell leukemia/lymphoma patient treated with pretransplant mogamulizumab.
P2860
Pretransplant mogamulizumab against ATLL might increase the risk of acute GVHD and non-relapse mortality.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Pretransplant mogamulizumab ag ...... VHD and non-relapse mortality.
@en
Pretransplant mogamulizumab ag ...... VHD and non-relapse mortality.
@nl
type
label
Pretransplant mogamulizumab ag ...... VHD and non-relapse mortality.
@en
Pretransplant mogamulizumab ag ...... VHD and non-relapse mortality.
@nl
prefLabel
Pretransplant mogamulizumab ag ...... VHD and non-relapse mortality.
@en
Pretransplant mogamulizumab ag ...... VHD and non-relapse mortality.
@nl
P2093
P2860
P356
P1476
Pretransplant mogamulizumab ag ...... VHD and non-relapse mortality.
@en
P2093
P2860
P2888
P304
P356
10.1038/BMT.2015.315
P407
P577
2015-12-21T00:00:00Z